TimesSquare Capital Management LLC Has $37.57 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

TimesSquare Capital Management LLC lessened its position in shares of Repligen Co. (NASDAQ:RGEN) by 5.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 260,992 shares of the biotechnology company’s stock after selling 14,635 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Repligen were worth $37,567,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Ballentine Partners LLC lifted its stake in Repligen by 4.0% in the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 72 shares during the period. CIBC Asset Management Inc lifted its stake in Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 81 shares during the period. MML Investors Services LLC lifted its stake in Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after buying an additional 89 shares during the period. GAMMA Investing LLC lifted its stake in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 90 shares during the period. Finally, Louisiana State Employees Retirement System lifted its stake in Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on RGEN shares. Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, HC Wainwright cut their price objective on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $182.91.

Repligen Trading Down 1.2 %

Shares of Repligen stock opened at $145.18 on Wednesday. The business’s 50 day simple moving average is $155.26 and its 200 day simple moving average is $148.82. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $207.87. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.